(2021) Bedaquiline: Current status and future perspectives. Journal of global antimicrobial resistance. pp. 48-59. ISSN 2213-7173 (Electronic) 2213-7165 (Linking)
Full text not available from this repository.
Abstract
The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent.
| Item Type: | Article | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creators: |
|
||||||||||||||||||||
| Keywords: | Bedaquiline Multidrug resistance Mycobacterium tuberculosis Tuberculosis | ||||||||||||||||||||
| Divisions: | |||||||||||||||||||||
| Page Range: | pp. 48-59 | ||||||||||||||||||||
| Journal or Publication Title: | Journal of global antimicrobial resistance | ||||||||||||||||||||
| Journal Index: | Pubmed | ||||||||||||||||||||
| Volume: | 25 | ||||||||||||||||||||
| Identification Number: | https://doi.org/10.1016/j.jgar.2021.02.017 | ||||||||||||||||||||
| ISSN: | 2213-7173 (Electronic) 2213-7165 (Linking) | ||||||||||||||||||||
| Depositing User: | مهندس مهدی شریفی | ||||||||||||||||||||
| URI: | http://eprints.medilam.ac.ir/id/eprint/3378 |
Actions (login required)
 |
View Item |